Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Letters to the Editor

Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial

St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds
King’s College Hospital, National Institute for Health and Care Research (NIHR) Wellcome Trust King’s Clinical Research Facility, London
St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds
St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds
King’s College Hospital, National Institute for Health and Care Research (NIHR) Wellcome Trust King’s Clinical Research Facility, London
Alexion, AstraZeneca Rare Disease, Boston, MA
Alexion, AstraZeneca Rare Disease, Boston, MA
Alexion, AstraZeneca Rare Disease, Boston, MA
Alexion, AstraZeneca Rare Disease, Boston, MA
St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds
King’s College Hospital, National Institute for Health and Care Research (NIHR) Wellcome Trust King’s Clinical Research Facility, London, UK; King’s College London, London
Haematologica Early view Nov 28, 2024 https://doi.org/10.3324/haematol.2024.285553

Data Supplements

Figures & Tables

Article Information

Early view : Letters to the Editor
 
DOI
https://doi.org/10.3324/haematol.2024.285553
Pubmed
39605209
 
Published
2024-11-28
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Article Usage

Online Views
676
PDF Downloads
215

Statistics from Altmetric.com

No Data
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2025 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online